Selinexor - Karyopharm Therapeutics

Drug Profile

Selinexor - Karyopharm Therapeutics

Alternative Names: CRM1-nuclear-export-inhibitor; KPT-330

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karyopharm Therapeutics
  • Developer Barbara Ann Karmanos Cancer Institute; Cardiff University; Dana-Farber Cancer Institute; Erasmus MC; H. Lee Moffitt Cancer Center and Research Institute; Karyopharm Therapeutics; Lymphoma Academic Research Organisation; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National University Hospital (Singapore); Rigshospitalet; Sheba Medical Center; St. Jude Childrens Research Hospital; The Ohio State University Comprehensive Cancer Center; University Health Network; University of Chicago; University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center; Weill Cornell Medical College
  • Class Acrylamides; Antineoplastics; Hydrazines; Pyrazines; Small molecules
  • Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma; Soft tissue sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Liposarcoma; Multiple myeloma
  • Phase II Acute myeloid leukaemia; Breast cancer; Cervical cancer; Cutaneous T cell lymphoma; Diffuse large B cell lymphoma; Endometrial cancer; Glioblastoma; Myelodysplastic syndromes; Neuroendocrine tumours; Ovarian cancer; Peripheral T-cell lymphoma; Prostate cancer; Small cell lung cancer; Squamous cell cancer; Thymoma
  • Phase I/II Chronic myelomonocytic leukaemia; Non-Hodgkin's lymphoma; Soft tissue sarcoma
  • Phase I B cell lymphoma; Chronic lymphocytic leukaemia; Colorectal cancer; Diabetic foot ulcer; Gastric cancer; Malignant melanoma; Oesophageal cancer; Osteosarcoma; Rectal cancer; Solid tumours
  • Preclinical Myelofibrosis; Non-small cell lung cancer

Most Recent Events

  • 12 Oct 2017 Selinexor licensed to Ono Pharmaceutical in Japan, South Korea, Taiwan, Hong Kong, and South East Asia (ASEAN countries)
  • 20 Sep 2017 Phase-III SEAL clinical trial in Liposarcoma (Late-stage disease, Inoperable/Unresectable, In children, In adolescents, In adults) in Europe, Canada, USA before 20 September 2017 (PO)
  • 20 Sep 2017 Karyopharm Therapeutics announces intention to submit NDA for oral selinexor to FDA for Liposarcoma in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top